Concepción Núñez1, M Carmen Cénit1, Roberto Alvarez-Lafuente2, Jordi Río3, Miguel Fernández-Arquero1, Rafael Arroyo2, Xavier Montalbán3, Oscar Fernández4, Begoña Oliver-Martos5, Laura Leyva5, Manuel Comabella3, Elena Urcelay1. 1. Immunology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 2. Multiple Sclerosis Unit, Neurology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 3. Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain. 4. Servicio de Neurología, Instituto de Neurociencias Clínicas, Hospital Regional Universitario, Málaga, Spain. 5. Laboratorio de Investigación, Instituto de Neurociencias Clínicas, Hospital Regional Universitario, Málaga, Spain.
Abstract
BACKGROUND: Recombinant interferon β (IFNβ) is a first-line therapy for relapsing-remitting multiple sclerosis (MS), with a proven effect on the inflammatory activity. Neutralising antibodies against IFNβ (NAbs) promote a loss of IFNβ bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. We investigated the contribution conferred by HLA alleles on the development of NAbs in independent cohorts of Southern Europe. METHODS: Serum NAbs from 610 MS patients with HLA-genotype data were evaluated by cytopathic effect assay: negative tests included at least one negative result (NAb titres<20 NU/mL) after 1 year treatment; NAb-titres ≥20 NU/mL were positive tests and NAb titres ≥150 NU/mL in any test were classified as high-titre positives. RESULTS: The combined presence of DRB1*07/DQA1*02 with A*26 or B*14 was found in 20% of patients with NAbs at high titres, but only in 5.4% of NAb-negative patients (p=0.00052, OR (95% CI) 4.34 (1.85 to 10.13)). The DRB1*04:01 allele was also more frequently carried by patients with high titres of NAbs (10% vs 4.5%; p=0.046, OR (95% CI) 2.38 (0.93 to 5.92)). The alleles carried at a significantly lower frequency in patients with high persistent NAbs corresponded to the A*11 allele (3.3% vs 13.8%; p=0.023, OR (95% CI) 0.22 (0.02 to 0.87)), as well as the DRB1*03/DQA1*05/DQB1*02 haplotype (16.3% vs 26.8%; p=0.02, OR (95% CI) 0.53 (0.27 to 1.03)) and the DRB1*13/DQA1*01:03/DQB1*06:03 haplotype (2.5% vs 9.1%; p=0.045, OR (95% CI) 0.25 (0.03 to 1.02)). CONCLUSIONS: 50% of the studied MS patients carried some of the five independently associated HLA allele/allele combinations described in this work. This relevant percentage of patients could benefit a therapeutic decision. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Recombinant interferon β (IFNβ) is a first-line therapy for relapsing-remitting multiple sclerosis (MS), with a proven effect on the inflammatory activity. Neutralising antibodies against IFNβ (NAbs) promote a loss of IFNβ bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. We investigated the contribution conferred by HLA alleles on the development of NAbs in independent cohorts of Southern Europe. METHODS: Serum NAbs from 610 MSpatients with HLA-genotype data were evaluated by cytopathic effect assay: negative tests included at least one negative result (NAb titres<20 NU/mL) after 1 year treatment; NAb-titres ≥20 NU/mL were positive tests and NAb titres ≥150 NU/mL in any test were classified as high-titre positives. RESULTS: The combined presence of DRB1*07/DQA1*02 with A*26 or B*14 was found in 20% of patients with NAbs at high titres, but only in 5.4% of NAb-negative patients (p=0.00052, OR (95% CI) 4.34 (1.85 to 10.13)). The DRB1*04:01 allele was also more frequently carried by patients with high titres of NAbs (10% vs 4.5%; p=0.046, OR (95% CI) 2.38 (0.93 to 5.92)). The alleles carried at a significantly lower frequency in patients with high persistent NAbs corresponded to the A*11 allele (3.3% vs 13.8%; p=0.023, OR (95% CI) 0.22 (0.02 to 0.87)), as well as the DRB1*03/DQA1*05/DQB1*02 haplotype (16.3% vs 26.8%; p=0.02, OR (95% CI) 0.53 (0.27 to 1.03)) and the DRB1*13/DQA1*01:03/DQB1*06:03 haplotype (2.5% vs 9.1%; p=0.045, OR (95% CI) 0.25 (0.03 to 1.02)). CONCLUSIONS: 50% of the studied MSpatients carried some of the five independently associated HLA allele/allele combinations described in this work. This relevant percentage of patients could benefit a therapeutic decision. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Natalia Kovalova; Michael D Knierman; Patricia L Brown-Augsburger; Victor J Wroblewski; Lukasz K Chlewicki Journal: Immunogenetics Date: 2019-11-27 Impact factor: 2.846
Authors: Delphine Bachelet; Signe Hässler; Cyprien Mbogning; Jenny Link; Malin Ryner; Ryan Ramanujam; Michael Auer; Poul Erik Hyldgaard Jensen; Nils Koch-Henriksen; Clemens Warnke; Kathleen Ingenhoven; Dorothea Buck; Verena Grummel; Andy Lawton; Naoimh Donnellan; Agnès Hincelin-Mery; Dan Sikkema; Marc Pallardy; Bernd Kieseier; Bernard Hemmer; Hans Peter Hartung; Per Soelberg Sorensen; Florian Deisenhammer; Pierre Dönnes; Julie Davidson; Anna Fogdell-Hahn; Philippe Broët Journal: PLoS One Date: 2016-11-02 Impact factor: 3.240
Authors: Kaarina Kowalec; Elaine Kingwell; Robert Carruthers; Ruth Ann Marrie; Sasha Bernatsky; Anthony Traboulsee; Colin J D Ross; Bruce Carleton; Helen Tremlett Journal: BMJ Open Date: 2017-06-02 Impact factor: 2.692
Authors: Flora S Kano; Flávia A Souza-Silva; Leticia M Torres; Barbara A S Lima; Taís N Sousa; Jéssica R S Alves; Roberto S Rocha; Cor J F Fontes; Bruno A M Sanchez; John H Adams; Cristiana F A Brito; Douglas E V Pires; David B Ascher; Ana Maria Sell; Luzia H Carvalho Journal: PLoS Negl Trop Dis Date: 2016-12-13
Authors: Till F M Andlauer; Jenny Link; Dorothea Martin; Malin Ryner; Christina Hermanrud; Verena Grummel; Michael Auer; Harald Hegen; Lilian Aly; Christiane Gasperi; Benjamin Knier; Bertram Müller-Myhsok; Poul Erik Hyldgaard Jensen; Finn Sellebjerg; Ingrid Kockum; Tomas Olsson; Marc Pallardy; Sebastian Spindeldreher; Florian Deisenhammer; Anna Fogdell-Hahn; Bernhard Hemmer Journal: BMC Med Date: 2020-11-04 Impact factor: 8.775